Mitochondrial therapy encompasses a broad and rapidly evolving set of treatments aimed at rescuing or replacing the energy-producing machinery inside cells. As of now, no cure exists for most mitochondrial diseases, and the standard of care still leans heavily on dietary supplements and symptom management whose benefits have not been definitively proven in large trials. But the field is moving on several fronts at once: researchers are editing mitochondrial DNA directly, transplanting whole organelles into damaged tissue, designing drugs that stabilize mitochondrial membranes, and even replacing defective mitochondria before a child is born. The gap between laboratory breakthroughs and routine clinical use remains wide, yet the pace of progress gives the field a genuinely different character than it had a decade ago.
Why Mitochondrial Disease Is Uniquely Difficult to Treat
Mitochondria are unusual in that they carry their own small genome, separate from the DNA in the cell nucleus. Mitochondrial diseases can arise from mutations in either genome: the mitochondrial DNA itself (mtDNA) or the nuclear genes that encode the vast majority of proteins mitochondria need to function. More than 250 disease-causing mtDNA mutations have been identified, and that number keeps growing as researchers discover additional nuclear-gene mutations involved in mitochondrial maintenance and metabolism.1PubMed. Mitochondrial DNA mutations and human disease Diseases caused by nuclear-gene mutations follow standard inheritance patterns, while those arising from mtDNA follow a maternal line and often coexist with normal copies of mtDNA in the same cell, a situation called heteroplasmy.2PubMed Central. Mitochondrial disorders of the nuclear genome
This dual-genome problem is the core reason treatment is so hard. A drug or gene therapy that fixes a nuclear mutation won’t help someone whose disease stems from mtDNA, and vice versa. Heteroplasmy adds another layer: the ratio of mutant to normal mtDNA varies between tissues and even between individual cells, so two patients with the same mutation can have wildly different symptoms. Because mitochondria are involved in almost every energy-intensive process in the body, symptoms span organs unpredictably, hitting the brain, heart, muscles, liver, or kidneys in different combinations. Any therapy needs to reach the right tissues, get inside the right compartment of the cell, and work alongside whatever percentage of healthy mitochondria remain.
What Patients Actually Receive Today
Walk into a mitochondrial disease clinic and you will likely leave with a cocktail of supplements: coenzyme Q10 (or its reduced form, ubiquinol), B vitamins, L-carnitine, alpha-lipoic acid, and creatine are common prescriptions. Some clinicians add high-dose vitamin C or vitamin E. The logic is straightforward: these molecules participate in energy metabolism and antioxidant defense, so replenishing them could help compensate for sluggish mitochondrial function. In practice, many physicians report observing real and sometimes dramatic improvement in individual patients, but controlled trials have not shown that these therapies reliably alter the course of the disease. Experts acknowledge that the evidence does not rise to the level required for universal use, even as they continue to prescribe them because the alternatives are limited and the supplements appear relatively safe.3PubMed Central. A modern approach to the treatment of mitochondrial disease
Patients themselves often feel strongly that supplements help. In a survey of mitochondrial disease patients, the majority of those taking dietary supplements reported health benefits, with perceived improvement typically beginning between two weeks and three months after starting. Side effects were mild in most cases, and only about 6% of patients stopped due to intolerance. The financial burden, however, is real: only about 9% had insurance coverage for these supplements, and among those paying out of pocket, most spent up to $500 per month. Roughly half of the patients surveyed believed supplements were the only intervention actually improving their symptoms, even though they were also using prescribed medications, physical therapy, or dietary changes.4PubMed Central. Mitochondrial disease patients’ perception of dietary supplements’ use That finding speaks to how limited current medical therapies feel from the patient’s perspective.
NAD+ Precursors and the Push to Refuel the Cell
One of the more promising supplement-adjacent strategies involves boosting levels of NAD+, a molecule that mitochondria depend on for virtually every metabolic reaction. NAD+ levels decline with age and in mitochondrial disease. Two precursors, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), have attracted intense interest because they can raise NAD+ levels in cells and tissues. Once inside the cell, NAD+ activates a family of enzymes called sirtuins, which in turn stimulate mitochondrial biogenesis and improve the cell’s ability to burn fuel and neutralize damaging free radicals.5PubMed Central. NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health
In mice, long-term NMN supplementation increased mitochondrial respiratory capacity in skeletal muscle and reversed some age-related gene expression changes. NR supplementation in mouse models boosted NAD+ levels, activated sirtuins, enhanced oxidative metabolism, and protected against obesity-related metabolic problems, suggesting it could serve as a nutritional approach for disorders linked to defective mitochondrial function.6Cell Metabolism. The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity These results are encouraging but still mostly preclinical. Human trials are underway for NR and NMN across various conditions, but we don’t yet know whether the animal findings will translate into meaningful clinical benefit for people with primary mitochondrial disease.
Elamipretide and the Membrane Approach
Rather than trying to replace missing molecules, some researchers are going after the structure of the mitochondrion itself. Elamipretide (also known by its research name SS-31) is a small synthetic peptide that targets the inner mitochondrial membrane. It works by binding to cardiolipin, a specialized fat molecule found almost exclusively in that membrane. Cardiolipin is essential for maintaining the folded cristae structures where energy production happens. When cardiolipin is damaged or disorganized, cristae collapse, ATP output drops, and harmful reactive oxygen species leak out.7PubMed Central. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential
By stabilizing cardiolipin, elamipretide props up cristae architecture, reduces oxidative stress, and improves ATP production.8PubMed Central. Mitochondrial protein interaction landscape of SS-31 The drug has been tested in clinical trials for Barth syndrome (a genetic disorder of cardiolipin metabolism) and for other mitochondrial myopathies. Results have been mixed: some patients showed functional improvement, but the drug has not yet received broad regulatory approval for mitochondrial disease. The concept behind elamipretide, though, represents a meaningful shift in thinking: rather than supplementing a missing cofactor, you’re reinforcing the physical platform on which the entire energy machinery sits.
Transplanting Mitochondria Directly Into Damaged Tissue
Perhaps the most dramatic experimental approach is mitochondrial transplantation: taking healthy, functioning mitochondria from one tissue and injecting them into damaged cells. This idea sounded improbable when it was first proposed, because mitochondria are fragile organelles, and getting them inside another cell seemed like a long shot. Yet animal studies have shown that exogenous mitochondria can be internalized by host cells and can improve function.
In a cardiac arrest model, researchers labeled isolated mitochondria with a fluorescent tracker and injected them through the femoral vein. Within four hours, labeled mitochondria appeared in the inner wall of the heart, as well as in the outer wall and middle muscle layers.9eLife. Transplantation of exogenous mitochondria mitigates myocardial dysfunction after cardiac arrest In a related rat model, transplantation of autologous mitochondria (taken from the animal’s own body) rescued hippocampal brain cells from the damage caused by interrupted blood flow and reduced neurological impairment after cardiac arrest.10PubMed. Neuroprotective effect of autologous mitochondrial transplantation against global ischemia/reperfusion injury in a rat model of cardiac arrest
Clinical translation has already started in a limited way. Early human applications involved direct injection of mitochondria into the heart muscle at multiple sites in children whose hearts could not be weaned off bypass after surgery. Since 2016, researchers have also explored intracoronary delivery, which is less invasive and could reach more tissue.11Life Medicine. Mitochondrial transplantation for the treatment of cardiac and noncardiac diseases: mechanisms, prospective, and challenges The biggest questions still unanswered are how long transplanted mitochondria survive, whether they replicate inside the host cell, and how to scale a process that currently requires harvesting organelles in real time during surgery.
Editing Mitochondrial DNA
Gene therapy for nuclear-gene disorders has made remarkable strides, but editing mtDNA is a different beast. The standard CRISPR-Cas9 system cannot easily be imported into mitochondria. Researchers have instead developed specialized tools, most prominently DdCBE (DddA-derived cytosine base editors), which can convert one DNA letter to another inside the mitochondrial genome without needing to cut both strands of DNA.
In a 2025 study, scientists used a DdCBE to introduce a compensatory edit in mice carrying a disease-causing mutation in a mitochondrial transfer RNA gene. The original mutation destabilized a critical structural element of the tRNA. By editing a second position in the same gene, researchers restored the tRNA’s secondary structure. In cell culture, this approach increased the amount of the affected tRNA by editing up to 78% of the mtDNA copies in the cell.12PubMed. Correcting a pathogenic mitochondrial DNA mutation by base editing in mice This is not a cure delivered to a living patient, but it is the clearest proof yet that precise mtDNA editing is feasible in a mammalian system. The path from a mouse cell line to a human therapy will be long, requiring safe delivery vehicles, tissue-specific targeting, and regulatory frameworks that don’t yet exist for this class of intervention.
For diseases caused by nuclear-gene mutations, adeno-associated virus (AAV) gene therapy is further along. In Leber hereditary optic neuropathy (LHON), a condition that destroys retinal ganglion cells and causes blindness, researchers tested two AAV-based strategies in a mouse model. One delivered a corrected copy of the affected gene into the mitochondria, while the other used an “allotopic” approach that placed the gene in the nucleus and attached a targeting signal to shuttle the protein back into mitochondria. Both approaches preserved retinal function over 15 months, but the mitochondria-targeted approach worked significantly better at protecting the small nerve fibers that are preferentially lost in human LHON.13PubMed Central. Comparison of different gene-therapy methods to treat Leber hereditary optic neuropathy in a mouse model
Preventing Transmission Before Birth
Mitochondrial replacement therapy (MRT) takes a fundamentally different tack: instead of fixing defective mitochondria, you replace them before conception. In the best-known technique, spindle transfer, a mother’s chromosomes are removed from her egg and placed into a donor egg whose nucleus has been removed but whose healthy mitochondria remain. The resulting embryo has nuclear DNA from both parents and mitochondrial DNA from the donor, which is why the procedure has been called “three-parent IVF” in the press.
The first reported live birth from spindle transfer involved a woman who carried a severe Leigh syndrome mutation. Her reconstituted embryo had a mutation load of only about 5.7%, and after birth the child’s tissues tested between roughly 2% and 9%, well below the threshold at which symptoms typically appear.14Reproductive BioMedicine Online. Live birth derived from oocyte spindle transfer to prevent mitochondrial disease The procedure appeared to work as designed in that case. However, subsequent data from children born after spindle transfer suggest that “reversal” of the mother’s mtDNA, meaning that the tiny carryover of maternal mitochondria can expand over time, is relatively common. This means the risk of disease transmission may not be entirely eliminated.15Human Reproduction. O-066 Mitochondrial DNA ‘reversal’ is common in children born following meiotic spindle transfer, potentially reducing the efficacy of mitochondrial replacement therapies Reversal is one of the most closely watched problems in the field, because it could undermine the entire rationale for MRT.
Regulation of MRT varies sharply by country. The United Kingdom approved clinical use of MRT under regulated conditions, while the United States has effectively blocked it through a congressional rider prohibiting the FDA from considering clinical applications. Canada, Germany, Australia, Israel, and Singapore each have their own policy frameworks at various stages of development.16PubMed. The Regulation of Mitochondrial Replacement Techniques Around the World Ethics panels in both the UK and the US have drawn a line between mitochondrial and nuclear genetic modification, noting that mtDNA is not associated with the traits the public typically thinks of as genetic identity and that the potential for enhancement is limited.17Journal of Law and the Biosciences. Mitochondrial replacement therapy: the UK and US regulatory landscapes Some ethicists have recommended that children born via MRT be told about their conception by adulthood and that sex selection be used alongside MRT to prevent transmission of any residual maternal mtDNA to future generations.18PubMed Central. The ethical challenges of the clinical introduction of mitochondrial replacement techniques
Clearing Out Damaged Mitochondria With Mitophagy Activators
A complementary strategy to fixing or replacing mitochondria is accelerating the cell’s natural process for getting rid of broken ones. Mitophagy is the selective recycling of damaged mitochondria. When it works well, cells maintain a healthy population of functional organelles. When it stalls, damaged mitochondria accumulate, leak free radicals, and contribute to disease progression.
Urolithin A, a compound produced by gut bacteria when they metabolize certain plant polyphenols found in pomegranates and berries, has emerged as one of the most studied mitophagy activators. In mouse models of Duchenne muscular dystrophy (DMD), urolithin A rescued the stalled mitophagy process, increased respiratory capacity in skeletal muscle, and improved the regenerative ability of muscle stem cells, leading to improved muscle function and increased survival.19PubMed. Urolithin A improves muscle function by inducing mitophagy in muscular dystrophy In aging-focused research, early treatment with urolithin A prevented age-related cognitive decline in mice, though notably, starting treatment late in life did not reverse impairment that had already set in.20PubMed Central. Early mitophagy activation by Urolithin A prevents, but late activation does not reverse, age-related cognitive impairment That timing finding matters: it suggests mitophagy-boosting therapies may be more useful for prevention and early intervention than for rescuing late-stage damage.
Mitochondria as a Cancer Target
Cancer cells were long thought to rely almost entirely on sugar fermentation (the Warburg effect), but it is now clear that many tumors, and especially drug-resistant cancer stem cells, depend heavily on mitochondrial energy production through oxidative phosphorylation (OXPHOS). This dependency has made mitochondrial metabolism a target for overcoming drug resistance. OXPHOS inhibitors have shown the ability to improve treatment responses in laboratory models of melanoma, lymphoma, colon cancer, leukemia, and pancreatic cancer.21PubMed Central. The Effect of Oxidative Phosphorylation on Cancer Drug Resistance
Getting these drugs into tumors without poisoning healthy tissue is the main obstacle. Several OXPHOS inhibitors have reached clinical trials, but moderate responses and substantial toxicity have so far hampered clinical adoption because these drugs suppress energy production in normal cells too.22PubMed. Mitochondria Targeting of Oxidative Phosphorylation Inhibitors to Alleviate Hypoxia and Enhance Anticancer Treatment Efficacy One promising delivery strategy exploits the fact that mitochondria carry a strong negative electrical charge across their inner membrane. Triphenylphosphonium (TPP+), a positively charged chemical group, naturally accumulates inside mitochondria because of this voltage difference.23PubMed Central. Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy Researchers have attached TPP+ to chemotherapy drugs packaged in nanocrystals; in cell studies, these mitochondria-targeted nanocrystals were substantially more toxic to drug-resistant breast cancer cells than the free drug alone, because they collapsed mitochondrial membrane potential directly at the source.24PubMed Central. Triphenylphosphonium-modified mitochondria-targeted paclitaxel nanocrystals for overcoming multidrug resistance If this kind of targeting can be refined for human use, it could make OXPHOS inhibition practical without the systemic side effects that have held the approach back.
Better Biomarkers Are Changing the Landscape
One underappreciated reason mitochondrial therapies have been slow to prove themselves in trials is the difficulty of measuring whether a treatment is actually working. Mitochondrial diseases affect different organs unpredictably, and traditional endpoints like muscle biopsies are invasive. A new generation of blood-based biomarkers is starting to change this.
Two circulating proteins, FGF21 and GDF15, have shown particular promise. In children with primary mitochondrial disorders, FGF21 levels correlated with disease severity, meaning that higher levels corresponded to worse clinical scores.25PubMed Central. Circulating FGF21 and GDF15 as Biomarkers for Screening, Diagnosis, and Severity Assessment of Primary Mitochondrial Disorders in Children Alongside these, researchers are exploring neurofilament light chain (NfL) as a marker of neurological damage and NAD+-related metabolic signatures as indicators of how well the cell’s energy machinery is performing. The eventual goal is an integrated set of molecular markers that can track disease progression, confirm that a therapy is hitting its target, and provide measurable endpoints for clinical trials.26PubMed Central. Non-invasive biomarkers for diagnosis and monitoring of primary mitochondrial diseases Without reliable biomarkers, even a genuinely effective drug can fail a clinical trial simply because the study couldn’t detect its benefit over the noise of a highly variable disease.
Mitochondrial Dynamics in Heart Disease
Beyond rare genetic conditions, mitochondrial dysfunction plays a role in far more common diseases. In diabetic cardiomyopathy, the heart muscle gradually weakens as chronically elevated blood sugar damages mitochondria. One of the key mechanisms involves a protein called Mfn2, which normally helps mitochondria fuse together into healthy networks. In diabetic mouse hearts, Mfn2 levels drop, mitochondria fragment into small dysfunctional units, and heart function declines. When researchers restored Mfn2 expression using an adenovirus vector in diabetic mice, mitochondrial fragmentation reversed, and cardiac function improved measurably: the heart’s ejection fraction increased, heart rate partially recovered, and diastolic function got better.27PubMed Central. Targeting mitochondrial dynamics by regulating Mfn2 for therapeutic intervention in diabetic cardiomyopathy
This line of work illustrates why the scope of “mitochondrial therapy” extends well beyond the orphan diseases that first drove the field. Mitochondrial dysfunction is a shared feature of heart failure, diabetes, neurodegeneration, and aging itself. Therapies originally developed for rare mitochondrial myopathies may eventually find their largest patient populations in these common conditions. Researchers have identified mitochondrial-targeted strategies as worth exploring for neuroprotection in Parkinson’s disease, for example, where dysfunction of the mitochondrial electron transport chain is one of the earliest detectable abnormalities.28PubMed Central. Mitochondrial therapies for Parkinson’s disease
Exercise and Diet as Mitochondrial Medicine
It would be misleading to discuss mitochondrial therapy entirely in terms of drugs and gene editing without acknowledging that the most proven way to improve mitochondrial function in living humans is exercise. Aerobic training stimulates the growth of new mitochondria, improves their efficiency, and clears damaged ones through mitophagy. For people with mild mitochondrial disease, carefully supervised exercise programs are often recommended alongside supplements, though the intensity needs to be calibrated to avoid triggering metabolic crises.
Dietary strategies can amplify these effects. In animal models, a ketogenic diet combined with exercise training produced additive or synergistic activation of pathways involved in mitochondrial biogenesis, fatty acid oxidation, and the quality-control processes that govern mitochondrial shape and turnover.29PubMed Central. Combined effects of a ketogenic diet and exercise training alter mitochondrial and peroxisomal substrate oxidative capacity in skeletal muscle Ketogenic diets are not universally appropriate for mitochondrial disease patients, especially those with certain fat-oxidation defects, so medical supervision is essential. But for some patients, the combination of metabolic dietary shifts and graded exercise may do more for mitochondrial health than any pill currently available.